Recently diverse drug screening approaches identified new compounds that specifically bind and modulate the activity of TRESK channels49, 50, 51 suggesting TRESK to represent a promising target molecule for the treatment of severe pain disorders such as migraine. Here, KCNK18 is linked to migraine disorder.